there is substantial evidence for the statin treatment in the context of secondary prevention of cardiovascular disease
however the short-term effects of early treatment with statins in patients after the onset of acute coronary syndromes (ACS) for the outcomes of death, myocardial infarction (MI), and stroke are unclear (1)
a meta-analysis involving 13 024 patients with acute coronary syndrome (ACS) was undertaken (1)
risk ratios for the combined end point of death, MI, and stroke for patients treated with early statin therapy compared with control therapy were 0.93 (95% confidence interval [CI], 0.80-1.09; P = .39) at 1 month and 0.93 (95% CI, 0.81-1.07; P = .30) at 4 months following ACS
there were no statistically significant risk reductions from statins for total death, total MI, total stroke, cardiovascular death, fatal or nonfatal MI, or revascularization procedures (percutaneous coronary intervention or coronary artery bypass graft surgery)
sensitivity analyses with restriction to trials of high quality or with additional data from a large trial using cerivastatin indicated summary risk ratios even closer to 1.
the study authors concluded, based on available evidence, initiation of statin therapy within 14 days following onset of ACS does not reduce death, MI, or stroke up to 4 months
a futher meta-analysis has also been undertaken examining the benefits of early statin therapy in ACS (2)
thirteen randomized controlled trials published before May 2006 were available, involving 17 963 adults (median number of patients, 135; median follow-up, 6 months)
survival curves revealed that this benefit begins to occur between 4 and 12 months, achieving statistical significance by 12 months
the authors concluded that early, intensive statin therapy reduces death and cardiovascular events after 4 months of treatment
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.